NCT04730583View on ClinicalTrials.gov

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

April 19, 2024

Study Completion Date

April 19, 2024

Conditions
Cutaneous Neurofibroma
Interventions
DRUG

Kybella

Injection into the cutaneous Neurofibromas lesion

DEVICE

1064nm laser

Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion

DEVICE

755nm Alexandrite Laser

Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion

Trial Locations (1)

02114

Wellman Center for Photomedicine, Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

Massachusetts General Hospital

OTHER